Wall Street Zen has upgraded Entrada Therapeutics (NASDAQ:TRDA) from a “sell” to a “hold” rating, contributing to a “Moderate Buy” consensus among analysts with an average target price of $18.50. Despite beating EPS expectations last quarter, the company significantly missed revenue targets and displays deeply negative net margins. Institutional ownership remains high at 86.39%, with several major hedge funds increasing or initiating positions.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Entrada Therapeutics (NASDAQ:TRDA) Stock Rating Upgraded by Wall Street Zen
Wall Street Zen has upgraded Entrada Therapeutics (NASDAQ:TRDA) from a “sell” to a “hold” rating, contributing to a “Moderate Buy” consensus among analysts with an average target price of $18.50. Despite beating EPS expectations last quarter, the company significantly missed revenue targets and displays deeply negative net margins. Institutional ownership remains high at 86.39%, with several major hedge funds increasing or initiating positions.